Dianthus Therapeutics, Inc. /DE/ Retained Earnings
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Retained Earnings of -$427.78 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-04
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$427.78M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$377.56M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$336.73M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$272.30M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$427.78M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | -$377.56M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | -$336.73M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | -$272.30M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$235.53M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$203.90M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | -$174.39M 10-K · filed 2026-03-09 | |
| 2024-09-30 | -$145.95M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | -$120.78M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$103.17M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$89.42M 10-K · filed 2025-03-11 | |
| 2023-09-30 | -$78.86M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$434.48M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | -$431.20M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$45.87M 10-K · filed 2024-03-21 | -$402.03M 10-K · filed 2023-03-23 |
| 2022-09-30 | -$78.90M 10-Q · filed 2023-11-09 | -$381.85M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$365.79M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$348.52M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$17.39M 8-K · filed 2023-12-21 | -$325.57M 10-K · filed 2022-03-08 |
| 2021-09-30 | -$306.27M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | -$288.85M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | -$271.92M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | -$254.43M 10-K · filed 2022-03-08 | |
| 2020-09-30 | -$236.26M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$218.59M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | -$199.51M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$179.50M 10-K · filed 2021-03-03 | |
| 2019-09-30 | -$156.26M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | -$135.27M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | -$117.56M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$102.73M 10-K · filed 2020-03-03 | |
| 2018-09-30 | -$86.05M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$70.03M 10-Q · filed 2018-08-09 | |
| 2017-12-31 | -$45.21M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |